ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Insulin

Also written as “Inhaled Insulin”, “Subcutaneous Insulin” and “Inhaled insulin”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Diabetes Mellitus · Non-alcoholic Fatty Liver Disease · Drug-Related Side Effects and Adverse Reactions, led by 14 companies.

Drug pageInsulin: every studyMany companies study it; this page follows only the 33 they lead. All 272 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jan 3, 200733 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizerits history only110 open or runningphase 4since Jan 3, 2007Aug 22, 2005none ahead
Oramedits history only50 open or runningphase 3since Oct 22, 2020Jun 19, 2013none ahead
Eli Lillyits history only40 open or runningphase 3since Oct 19, 2006Jun 20, 2003none ahead
Oshadi Drug Administrationits history only20 open or runningphase 2since Jan 17, 2013Jan 17, 2013none ahead
Sanofiits history only20 open or runningphase 4since Jul 23, 2014Sep 2, 2010none ahead
Baxter Healthcareits history only10 open or runningphase 1since Jul 31, 2006Jul 31, 2006none ahead
CPEX Pharmaceuticalsits history only10 open or runningphase 2since Feb 23, 2009Feb 23, 2009none ahead
Generex Biotechnology10 open or runningphase 3since Apr 24, 2008Apr 24, 2008none ahead
Getz Pharmaits history only10 open or runningphase 4since Dec 16, 2021Dec 16, 2021none ahead
Nastech Pharmaceuticalits history only10 open or runningphase 2since Feb 7, 2008Feb 7, 2008none ahead

Also a collaborator on its studies: Integrium, Alkermes, Kowa, Nextrials, eResearch Technology, Hoffmann-La Roche, ACM Pivotal Global Central Laboratory and Novo Nordisk.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Generex Biotechnology only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Apr 24, 2008First study: phase 3 study in Diabetes MellitusFirst studyNCT00668850 · 500 enrolled · United States, Bulgaria, Canada and more
  2. Dec 9, 2019Named insulinINNProposed as its International Nonproprietary Name in WHO's List 122

TargetBeta

INSR →read by rule
“Insulin receptor agonist”ChEMBL 37, by rule

Other programs on INSR

ProgramCompanyFurthest phaseStudies
Insulin GlargineruleSanofiphase 4190
Insulin AspartruleNovo Nordiskphase 4146
insulin degludecruleNovo Nordiskphase 4108
insulin glulisineruleSanofiphase 443
insulin icodecruleNovo Nordiskphase 430
linsitinibruleAstellas Pharmaphase 313
LY3938577Eli Lillyphase 23

Studies

The one study Generex Biotechnology leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00668850Diabetes Mellitus · United States, Bulgaria, Canada and more3UNKNOWNAug 2011500

How it is read

Names in the registry

  • “Insulin”, 13 entries
  • “Inhaled Insulin”, 5 entries
  • “Subcutaneous Insulin”, 3 entries
  • “Inhaled insulin”, 3 entries
  • “Inhaled Insulin (Exubera)”, 2 entries

Codes read as this program: LY041001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.